Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LXRX NASDAQ:MNKD NASDAQ:VNDA NASDAQ:ZBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLXRXLexicon Pharmaceuticals$2.16-3.1%$1.80$0.62▼$2.53$959.46M0.973.07 million shs1.63 million shsMNKDMannKind$3.38+2.1%$2.79$2.23▼$6.51$1.04B1.046.74 million shs4.61 million shsVNDAVanda Pharmaceuticals$6.19-0.3%$7.08$4.14▼$9.94$372.24M0.651.20 million shs884,074 shsZBIOZenas BioPharma$18.97-4.4%$20.51$8.91▼$44.60$1.20B-0.61555,534 shs342,230 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLXRXLexicon Pharmaceuticals-3.14%-3.14%+18.68%+46.94%+252.02%MNKDMannKind+2.11%+9.39%+23.36%-38.99%-18.94%VNDAVanda Pharmaceuticals-0.32%-1.43%-9.37%+7.47%+43.29%ZBIOZenas BioPharma-4.39%+3.44%-5.48%-26.70%+73.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLXRXLexicon Pharmaceuticals$2.16-3.1%$1.80$0.62▼$2.53$959.46M0.973.07 million shs1.63 million shsMNKDMannKind$3.38+2.1%$2.79$2.23▼$6.51$1.04B1.046.74 million shs4.61 million shsVNDAVanda Pharmaceuticals$6.19-0.3%$7.08$4.14▼$9.94$372.24M0.651.20 million shs884,074 shsZBIOZenas BioPharma$18.97-4.4%$20.51$8.91▼$44.60$1.20B-0.61555,534 shs342,230 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLXRXLexicon Pharmaceuticals-3.14%-3.14%+18.68%+46.94%+252.02%MNKDMannKind+2.11%+9.39%+23.36%-38.99%-18.94%VNDAVanda Pharmaceuticals-0.32%-1.43%-9.37%+7.47%+43.29%ZBIOZenas BioPharma-4.39%+3.44%-5.48%-26.70%+73.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLXRXLexicon Pharmaceuticals 2.33Hold$4.55110.65% UpsideMNKDMannKind 2.60Moderate Buy$8.84161.65% UpsideVNDAVanda Pharmaceuticals 2.50Moderate Buy$14.30131.02% UpsideZBIOZenas BioPharma 2.56Moderate Buy$44.29133.45% UpsideCurrent Analyst Ratings BreakdownLatest VNDA, ZBIO, LXRX, and MNKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026ZBIOZenas BioPharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/15/2026ZBIOZenas BioPharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$44.005/14/2026ZBIOZenas BioPharma Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$21.00 ➝ $22.005/14/2026ZBIOZenas BioPharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/11/2026LXRXLexicon Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.30 ➝ $3.105/11/2026VNDAVanda Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$24.00 ➝ $21.005/7/2026MNKDMannKind Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$8.00 ➝ $10.005/7/2026MNKDMannKind HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $10.005/7/2026MNKDMannKind Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$3.50 ➝ $4.755/7/2026MNKDMannKind MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$8.00 ➝ $7.004/28/2026MNKDMannKind Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.00 ➝ $8.00(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLXRXLexicon Pharmaceuticals$49.80M19.27N/AN/A$0.46 per share4.70MNKDMannKind$360.78M2.89$0.06 per share53.49($0.19) per share-17.79VNDAVanda Pharmaceuticals$216.10M1.72N/AN/A$4.67 per share1.33ZBIOZenas BioPharmaN/AN/AN/AN/A$5.32 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLXRXLexicon Pharmaceuticals-$50.34M-$0.07N/AN/AN/A-37.46%-18.64%-11.79%8/5/2026 (Estimated)MNKDMannKind$5.86M-$0.07N/A22.53N/A-6.63%-11.21%-3.92%8/5/2026 (Estimated)VNDAVanda Pharmaceuticals-$220.47M-$4.05N/AN/AN/A-109.99%-32.26%-23.43%7/30/2026 (Estimated)ZBIOZenas BioPharma-$377.74M-$8.47N/AN/AN/AN/A-99.99%-58.06%8/11/2026 (Estimated)Latest VNDA, ZBIO, LXRX, and MNKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ZBIOZenas BioPharma-$1.4742-$1.46+$0.0142-$1.46$25.00 millionN/A5/7/2026Q1 2026LXRXLexicon Pharmaceuticals-$0.04-$0.0026+$0.0374N/A$9.79 million$21.10 million5/6/2026Q1 2026MNKDMannKind-$0.02-$0.05-$0.03-$0.05$105.38 million$90.17 million5/6/2026Q1 2026VNDAVanda Pharmaceuticals-$0.6880-$0.82-$0.1320-$0.82$54.98 million$51.72 million4/13/2026Q4 2025ZBIOZenas BioPharmaN/A-$1.10N/A-$0.98$40.00 millionN/A3/16/2026Q4 2025ZBIOZenas BioPharma-$1.22-$4.54-$3.32-$4.54$28.75 millionN/A3/5/2026Q4 2025LXRXLexicon Pharmaceuticals-$0.07-$0.04+$0.03-$0.04$3.14 million$5.49 million2/26/2026Q4 2025MNKDMannKind-$0.01-$0.05-$0.04-$0.05$99.85 million$111.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthLXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/AVNDAVanda PharmaceuticalsN/AN/AN/AN/AN/AZBIOZenas BioPharma$0.050.25%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLXRXLexicon Pharmaceuticals0.2418.8018.77MNKDMannKindN/A1.871.50VNDAVanda Pharmaceuticals0.012.162.15ZBIOZenas BioPharma1.0411.9411.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLXRXLexicon Pharmaceuticals74.70%MNKDMannKind49.55%VNDAVanda Pharmaceuticals88.14%ZBIOZenas BioPharmaN/AInsider OwnershipCompanyInsider OwnershipLXRXLexicon Pharmaceuticals14.00%MNKDMannKind2.60%VNDAVanda Pharmaceuticals10.00%ZBIOZenas BioPharma22.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLXRXLexicon Pharmaceuticals140444.20 million382.01 millionOptionableMNKDMannKind400308.95 million300.92 millionOptionableVNDAVanda Pharmaceuticals29060.13 million54.12 millionOptionableZBIOZenas BioPharmaN/A63.13 million49.24 millionN/AVNDA, ZBIO, LXRX, and MNKD HeadlinesRecent News About These CompaniesZenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 ...May 19, 2026 | markets.businessinsider.comHC Wainwright Predicts Lower Earnings for Zenas BioPharmaMay 19, 2026 | marketbeat.comZenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 CongressMay 19, 2026 | globenewswire.comZenas BioPharma (NASDAQ:ZBIO) CEO Leon Moulder, Jr. Purchases 60,000 SharesMay 19, 2026 | americanbankingnews.comZenas BioPharma (NASDAQ:ZBIO) CEO Purchases $1,012,800.00 in StockMay 19, 2026 | insidertrades.comZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 18, 2026 | globenewswire.comZenas BioPharma Advances Phase 3 Orelabrutinib Trial in Tough MS SegmentMay 18, 2026 | tipranks.comHead to Head Review: Zenas BioPharma (NASDAQ:ZBIO) vs. Elicio Therapeutics (NASDAQ:ELTX)May 18, 2026 | americanbankingnews.comVanguard Group Inc. Acquires 290,307 Shares of Zenas BioPharma, Inc. $ZBIOMay 16, 2026 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Raised to Sell at Wall Street ZenMay 16, 2026 | americanbankingnews.comZenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Consensus Recommendation of "Hold" from AnalystsMay 15, 2026 | americanbankingnews.comWhy Zenas BioPharma (ZBIO) Is Down 7.7% After Reporting a Sharply Wider Quarterly Net LossMay 14, 2026 | uk.finance.yahoo.comZenas BioPharma Stock Short Interest Report | NASDAQ:ZBIO | BenzingaMay 13, 2026 | benzinga.comZenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF InhibitorMay 13, 2026 | globenewswire.comZenas BioPharma Highlights Strong Q1 Progress and FinancingMay 13, 2026 | tipranks.comZenas BioPharma Reports Progress on Obexelimab and ZB021 Trials, Financial Milestones and Upcoming Regulatory SubmissionsMay 13, 2026 | quiverquant.comQZenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | globenewswire.comZenas BioPharma (ZBIO) to Release Quarterly Earnings on ThursdayMay 7, 2026 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Stock Price Up 7.7% - Still a Buy?May 4, 2026 | marketbeat.comZenas BioPharma rises as CEO continues insider purchasesApril 30, 2026 | msn.comZenas: 'Strong Buy' On Obexelimab Enhancement And Expected SLE Data Q4 2026April 30, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVNDA, ZBIO, LXRX, and MNKD Company DescriptionsLexicon Pharmaceuticals NASDAQ:LXRX$2.16 -0.07 (-3.14%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$2.18 +0.02 (+0.93%) As of 05/22/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.MannKind NASDAQ:MNKD$3.38 +0.07 (+2.11%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.40 +0.02 (+0.53%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Vanda Pharmaceuticals NASDAQ:VNDA$6.19 -0.02 (-0.32%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$6.17 -0.02 (-0.31%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.Zenas BioPharma NASDAQ:ZBIO$18.97 -0.87 (-4.39%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$19.05 +0.08 (+0.42%) As of 05/22/2026 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
